c="Serine" 1:0 1:0||t="medication"||cui="C0036720"||tot="Serine"||ns="-1000"
c="type IV osteogenesis imperfecta (OI" 1:12 1:16||t="problem"||cui="C0268363"||tot="Osteogenesis imperfecta type IV"||ns="-1000"
c="Serine" 2:0 2:0||t="medication"||cui="C0036720"||tot="Serine"||ns="-1000"
c="lethal type II osteogenesis imperfecta (OI" 2:15 2:20||t="problem"||cui="C0268358"||tot="Osteogenesis imperfecta, perinatal lethal"||ns="-937"
c="nonlethal OI" 2:25 2:26||t="problem"||cui="C0029434"||tot="Osteogenesis Imperfecta"||ns="-901"
c="moderately severe type IV OI" 2:33 2:37||t="problem"||cui="C0268363"||tot="Osteogenesis imperfecta type IV"||ns="-901"
c="moderately severe OI phenotype" 2:77 2:80||t="problem"||cui="C1836408"||tot="Severe phenotype"||ns="-875"
c="overmodified form" 2:126 2:127||t="treatment"||cui="C0013058"||tot="Dosage Form"||ns="-861"
